Piper Sandler raised the firm’s price target on Revolution Medicines (RVMD) to $120 from $75 and keeps an Overweight rating on the shares following quarterly results. The firm cites increased confidence in daraxonrasib and the addition of zoldonrasib to its model for the price target increase.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines price target raised to $115 from $109 at BofA
- Revolution Medicines price target raised to $144 from $100 at Wells Fargo
- Revolution Medicines: Advancing RAS Inhibitor Pipeline and Strong Cash Runway Support Buy Rating
- Revolution Medicines reports Q4 EPS ($1.86), consensus ($1.56)
- Revolution Medicines sees FY26 operating expenses $1.6B-$1.7B